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TESTING FOR DRUGS OF ABUSE:
METHODS AND RELIABILITY
Edward A. Kaufman, M.D.*
FOREWARD
Testing for drugs of abuse has become one of the most heated topics of our
times. Testing advocates cite safety hazards and the loss of tens of billions of
dollars in decreased productivity as a result of drug abuse on the job. Oppo-
nents are concerned about the challenge to individual rights implicit in some
forms of testing, and much has been said and written about the risks and
consequences of improperly conducted tests. The role of a responsible clini-
cal laboratory is neither to advocate nor to discourage the development of
drug testing programs, but rather to provide dear information on the avail-
able procedures and their limitations, to conduct those tests with impeccable
attention to accuracy and confidentiality, and to back up positive results with
flawless medico-legal documentation and expert witness testimony.
The sudden expansion of demand for drugs-of-abuse testing has given
rise to a growing number of hastily improvised testing services and new
specialty laboratories, and the questionable quality of these operations has
produced a great deal of bad publicity and costly litigation. Yet testing for
substances of abuse as performed at a reputable, well-established laboratory
is extremely accurate and reliable. A positive result obtained from such a
laboratory and backed by meticulous chain-of-custody documentation can
be accepted with virtual certainty as evidence of drug use.
Providing this degree of quality and reliablity is no easy matter, however.
The laboratory must be ever alert to the many technical and medico-legal
factors that can affect the viability of a test result. Although most of the news
media's ongoing debate about accuracy has focused on the testing process
itself, there are many steps that precede and follow the actual testing that
require an equal degree of care.
The purpose of this paper is to discuss the entire testing process, from
specimen collection and preparation (vital processes that are often beyond
the control of the laboratory) to test methods, quality assurance measures,
medico-legal documentation, and result reporting and interpretation. Each
of these steps demands careful attention, and the hallmark of a responsible,
quality-conscious laboratory is that it can offer a complete testing system that
focuses not only on the assays themselves but also on each of the necessary
precautions and transactions so crucial to the viability of test results.
* Vice-President, Industry Affairs, SmithKline Bio-Science Laboratories, Inc.,
Philadelphia, Pa.; M.D., Boston University School of Medicine; M.B.A., Stanford
Graduate School of Business.
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CHOOSING THE TYPE OF SPECIMEN
Urine
In most cases, urine is the specimen of choice for drug testing. Urine col-
lection is easy and noninvasive. Drugs are readily detected in urine speci-
mens, since this is the primary route by which drugs and their metabolites
are excreted from the body.
Blood
Analysis of blood specimens is useful for establishing the time of drug use,
since most drugs are quickly metabolized in blood and rapidly disappear
from detection. In addition, blood is collected by means of a "closed system,"
which greatly reduces the possibility of contamination of the sample. How-
ever, blood specimens must be obtained under sterile conditions by a trained
technician, and the procedure for drawing blood is necessarily invasive. Fur-
thermore, the rapid disappearance of drugs from blood makes their detec-
tion technically more difficult than in urine.
PREPARATION OF THE URINE SPECIMEN
Collection
The optimal method of collection is to have the participant urinate into a
collection container under observation. The specimen is then transferred to
one or two (optional) specimen bottles.
Checking Specimen Viability
As a check on specimen viability, the pH and specific gravity should be
determined using a residual specimen from the original collection container
(optional). These determinations should be confirmed by the laboratory be-
fore testing begins. A fresh, unadulterated specimen will have a pH between
5 and 8 and a specific gravity greater than 1.005. It has also been suggested
that the temperature of the specimen be measured immediately after collec-
tion. A reading approximating body temperature offers some degree of as-
surance that another specimen has not been substituted for the original.
Labeling
Each specimen bottle must bear a clearly legible name and/or identifica-
tion code.
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Tamper-Evident Tape
Specimen bottles are carefully sealed with tamper-evident tape to enable
laboratory technologists to recognize tampering and request a repeat
specimen.
The Requisition Form
A requisition form should be submitted stating the name and/or identifi-
cation code of the participant and the test to be performed.
Chain-of-Custody Documentation
The chain of custody must be dearly documented to make sure that test
results will be accepted as legal evidence ..Chain-of-custody forms should be
signed or initialed at each transfer of the specimen's custody.
Sealed Chain-of-Custody Bags
The taped specimen bottles, requisition form, and chain-of-custody form
should be sealed in a tamper-evident chain-of-custody bag before the speci-
men leaves the site of collection.
TRANSPORTING THE SPECIMEN
A well-established delivery system using laboratory-employed couriers is
an important element in maintaining specimen integrity and reliable chain-
of-custody documentation. Laboratory couriers are specially trained in
proper handling of specimens and in chain-of-custody requirements, en-
suring fast and legally supportable delivery of specimens to testing sites.
Although licensed commercial carriers and the United States mail can also
provide chain-of-custody documentation, use of laboratory couriers allows
an added degree of control over transportation procedures and delivery
times.
TESTING: A TWO-TIERED PROCESS
A responsible laboratory will issue a positive test result only if the drug or
drugs in question have been detected by two distinct tests using chemically
different analytic methods. The most practical means of fulfilling this re-
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quirement is to perform an initial screening test on all samples and then to
follow up with a confirmatory test on all samples that have been found to be
positive on the initial screen. If a sample is determined to be negative on the
screening test, or if the screening results are positive but the confirmatory
results are negative, the result reported for each drug is "None Detected."
Only if both the screening test and the confirmatory test are positive is a
report issued that a specific drug has been "Detected."
The Initial Screen
Screening can be defined as testing urine samples of completely unknown
composition specimens to determine the presence or absence of drugs and, if
present, their probable identity. The principle requirement of a screening
method is that it be highly sensitive. That is, a screening test should be very
sensitive to the presence of the substance for which the test is being con-
ducted. However, tests with a high degree of sensitivity tend to be less reli-
able in establishing a positive identity of the substance detected, and the very
sensitivity that makes the screen so useful can also result in misidentification
of chemically similar compounds. For example, some screening tests for am-
phetamines cross-react with phenylpropanolamine, a commonly used de-
congestant. This limited accuracy of screening tests has provided the news
media ample opportunity for questioning the reliability of drugs-of-abuse
testing as a whole, and indeed, screening tests should never be used without
automatic confirmatory testing of positive results by a more specific method.
Screening assays fall into two basic categories: immunologic assays and
thin-layer chromatography procedures.
Immunoassays. The present consensus seems to be that immunologic as-
says are the methods of choice for screening. One of the most widely used
assays is the enzyme-multiplied immunoassay technique, which is per-
formed using a kit manufactured by the Syva Company (a division of Syntex,
Inc., located in Palo Alto, California) under the trade name "EMIT." The
EMIT assay is similar in principle to other commonly used immunoassays,
including the enzyme-linked immunosorbent assay (ELISA) and the ra-
dioimmunoassay (RIA).
The EMIT system can be used to detect approximately 35 different drugs
of abuse. In screening for common drugs of abuse, up to 10 separate EMIT
assays may be performed, using 10 different sets of reagents. The more com-
mon drugs that can be detected with the EMIT screen include:
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Amphetamines
d-Amphetamine
Methamphetamine
Barbiturates
Amobarbital
Butabarbital
Pentobarbital
Phenobarbital
Benzodiazepines
Chlordiazepoxide (Librium)
Clonazepam (Clonopin)
Diazepam (Valium)
Flurazepam (Dalmane)
Oxazepam (Serax)
Opiates
Codeine
Heroin (detected as morphine)
Hydrocodone
Hydromorphone
Morphine
Other Drugs
Cannabinoids (marijuana metabolites)
Cocaine (detected as benzoylecgonine)
Methadone
Methaqualone (Quaalude)
Phencydidine (PCP)
Propoxyphene (Darvon)
The EMIT assay is performed by following a complex sequence of steps.
First a drop of urine is mixed with antibodies against the drug being sought,
known quantities of the drug labeled with an enzyme, and a substrate on
which the enyzme can act. The unlabeled drug in the specimen and the
added enzyme-labeled drug compete for binding with the antibodies. As a
result, the more unlabeled drug there is in the specimen, the more enzyme-
labeled drug is left free to react with the substrate. The enzyme-substrate
reaction causes a color change that is measured with a spectrophotometer.
The degree of color change represented by this measurement is proportional
to the amount of drug and/or drug metabolites present in the original
specimen.
Thin-Layer Chromatography (TLC). Thin-layer chromatography is a tradi-
tional analytic method that can be used to screen for a broader range of drugs
(as many as fifty) than the immunologic assays. TLC is a useful, sensitive
technique, but it is more labor-intensive and is significantly more dependent
on the analytic skill of the laboratory technologist than EMIT and other auto-
mated immunoassays. This method is most often applied in clinical settings,
especially when the cause of coma or suspected drug overdose must be de-
termined.
Confirmatory Testing
Although confirmatory techniques are as sensitive as screening tech-
niques, the primary criterion of confirmatory methods is that they be highly
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specific. That is, they must be very accurate at determining the absence of the
substance identified as present by the screen if in fact that substance is not
present in the specimen. Confirmatory tests should be performed on a sepa-
rate sample taken from the original specimen bottle (or, if two bottles are
submitted, taken from the second bottle) to eliminate possible errors in the
screening test. Commonly used confirmatory methods include high-
performance thin-layer chromatography (HPTLC), gas chromatography
(GC), and gas chromatography in conjunction with mass spectrometry
(GC/MS).
High-Performance Thin-Layer Chromatography (HPTLC). In thin-layer chro-
matography (TLC), an extract of urine is placed at the bottom of a thin glass
plate coated with grains of silica. The edge of the glass plate is then placed in a
solvent, which migrates up the plate, carrying the drug along with it. Differ-
ent drugs migrate different distances, depending on their physical and
chemical properties. The resulting drug deposits are invisible and need to be
"developed," much like photographic film. Identification of the drug is
based on the shape and color of these deposits as well as the distance they
travel.
In HPTLC, a finer, more uniform silica is used. This enhances separation
and permits more accurate drug identification. HPTLC is suitable as a confir-
matory test for certain drugs.
Gas Chromatography (GC). More technically known as gas-liquid chromato-
graphy, GC is initiated by injecting a small quantity of processed urine resi-
due into a chromatographic column -- a coiled glass tube lined with inert
liquid silicone, or an equivalent, and ranging in length from a few feet to
hundreds of yards. Some gas chromatographs contain two columns with
slight variations in retention characteristics, thus providing duplicate re-
sults. Immediately following injection, the sample is subjected to high heat
and vaporized. This vapor is then pushed through the tube by pressurized
neutral gas.
The gasified molecules of different drugs move through the tube at differ-
ent speeds, according to their individual chemical and physical properties.
At the far end of the column, the molecules enter a device called a detector.
This device breaks the molecules into electrically charged fragments called
ions. These ions create a current when they strike the detector, thus provid-
ing a means of measuring the time that has elapsed between sample injection
and detection. Since each drug moves through the column at its own unique
speed, these transit times, referred to in the laboratory as retention times, are
compared to known standard retention times for each of the drugs suspected
of being in the sample.
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Dual-column GC is considered by toxicologists to be one of the most reli-
able forms of confirmation for amphetamines, cocaine, benzoylecgonine
(the cocaine metabolite found in humans), PCP, and a number of other drugs
of abuse.
Gas Chromatography/Mass Spectrometry (GCIMS). GC/MS is a highly specific
analytical technique whereby vaporized drugs pass from the gas chromato-
graph into a special detection device known as a mass spectrometer. In the
mass spectrometer, the gasified molecules are bombarded and shattered by a
stream of electrons. Each drug has its own unique pattern of ions, which can
be identified on the basis of number and mass. These ions are directed
through a "gate," the size of which is progressively increased to admit ions of
successively greater mass, to reach the detector where the ions create a mea-
surable current.
The mass spectrometer requires only a fraction of a second to measure the
full range of ion fragment sizes in the sample. The resulting data are orga-
nized by a computer and displayed in a graph that shows the mass of the
various ion fragments and the number of ions of each mass. This unique ionic
pattern provides a "molecular fingerprint" that allows identification of the
drug through comparison with a computerized library of known molecular
fragmentation patterns.
GC/MS is considered one of the most accurate analytical methods for
identifying drugs in body fluids and is especially helpful in identifying mari-
juana and its metabolites (cannabinoids).
QUALITY ASSURANCE
Daily quality assurance procedures are essential in maintaining result reli-
ability. Quality assurance measures in a reputable laboratory should include
frequent analysis of standard and control specimens to monitor and recali-
brate analytic instruments, regular proficiency testing to maintain licensure
and accreditation, and blind submission of control samples as a means of
evaluating every step of the testing process.
Standard and Control Samples
Analytic instruments must be painstakingly recalibrated every day by
analyzing standard samples containing known quantities of drugs. Read-
ings for successive standards must be consistent. This process is essential for
ensuring the accuracy of test results.
Following the initial instrument calibration, control samples containing
known amounts of drug should be run with each batch of specimens to make
sure the instrument retains its accuracy. When results for the control sam-
ples are inaccurate, all of the specimens in the batch must be retested. At
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SmithKline Bio-Science Laboratories, controls are run before and after each
batch and following every tenth sample.
Proficiency Testing
To maintain licensure and certification, laboratories must undergo regular
proficiency testing. This testing requires the laboratory to analyze samples
submitted by state departments of health and such private groups as the
American Association for Clinical Chemistry and the College of American
Pathologists. The types of testing required for the samples is specified by the
testing agency, but the laboratory is not told which substances may or may
not be present or in what concentrations. Test results are reported to the
agencies, which base their accreditation on the attainment of set levels of
proficiency.
Blind Submission of Control Samples
Blind proficiency testing is an internal quality check performed by only
the very best laboratories; there are no commercially available blind testing
programs. This type of proficiency testing is very similar to the testing
described in the previous paragraph. Outside clients are asked to mix blind
samples with their own specimens. Laboratory personnel have no way of
knowing which samples in a batch, if any, are quality control samples. In this
way, the entire testing system can be evaluated, from courier pick-up to re-
porting of results. Blind proficiency testing is the only real way of making
sure that a laboratory is giving the necessary attention not only to the analyti-
cal procedures themselves, but to all the many contingent factors on which
accuracy and reliability depend.
TEST ACCURACY
"Accuracy" can be defined in a variety of different (and evasive) ways, but
the practical essence of the term can be found in a question asked by every
conscientious client: "What is the probability that a drug is really present in
the specimen when the test result is positive?" A responsible answer to this
question can be given only after performing a series of calculations to obtain
what is called the predictive value of a positive test. The predictive value
must be calculated on the basis of three statistical measures: sensitivity, spe-
cificity, and prevalence. Many claims have been issued about the sensitivity
and specificity of various tests, but none of these three values, quoted alone
or in combination, should be confused with accuracy.
Prevalence (Prey.)
Prevalence is a measure of the frequency with which an event occurs in the
population being studied. In substance abuse testing, prevalence is the fre-
[Vol. 2:1
TESTING FOR DRUGS OF ABUSE
quency with which one would expect to encounter drug users among a pop-
ulation of employees prior to testing. These data are derived from a com-
pany's experience and may be based on prior testing for that organization,
testing conducted for other institutions, or information provided by other
employers with similar employee profiles. A prevalence of 15% indicates
that 15 of every 100 employees can be expected to be drug users.
Sensitivity (Sens.)
Sensitivity represents the ability to detect a given substance with a test or
combination of tests. The sensitivity states the probability that known posi-
tive samples will actually test positive. For example, if a test identifies 95 of
every 100 known positive samples as positive, then that test has a sensitivity
of 95%.
Specificity (Spec.)
Specificity represents the ability to declare a sample negative when it is in
fact negative for a given substance. The specificity states the probability that
known negative samples will actually test negative. For example, if a test
identifies 90 of every 100 known negative samples as negative, then that test
has a specificity of 90%.
Predictive Value (PV)
The predictive value, or the probability that a positive test result has in fact
identified a true drug user, is calculated on the basis of a complex revision of
the foregoing three values using Bayes theorem:
PV = Prev. x Sens.
[Prev. x Sens.] + [(1-Prev.) x (1-Spec.)]
Using the examples given earlier:
Prevalence = 0.15
Sensitivity = 0.95
Specificity = 0.90
PV = 0.15 x 0.95 = 0.63
[0.15 x 0.95] + [0.85 x 0.10]
This means that if a positive result is obtained from the screening test,
there is a 63% probability that the test has correctly identified a drug user.
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Obviously, then, a sensitivity of 0.95 and a specificity of 0.90 do not necessar-
ily mean that the test is at least 90% accurate. This example can be considered
representative of an actual screening test. A drug use prevalence of 15% is
somewhat greater than average, but a screening test with a sensitivity of 95%
and a specificity of 90% would be considered a good test. Yet a positive result
could hardly be considered conclusive evidence of drug use.
This clearly illustrates why it is essential to follow everypositive screening
test with a confirmatory test. The confirmatory methods discussed in this
paper are highly specific, and a positive confirmatory test in conjunction
with a positive screening test raises the probability that the drug has been
correctly identified to more than 99.99%. That is, the predictive value in such
a case exceeds 99.99%. Thus the uncertainty is virtually eliminated, and the
result is highly reliable.
INTERPRETING TEST RESULTS
What Does a Positive Result Mean?
A confirmed positive result offers nearly 100% assurance that the speci-
men tested does in fact contain a drug or drugs. However, assays for drugs of
abuse do not indicate how the drugs were used, nor can they distinguish
between drugs that were obtained legally and drugs obtained or used ille-
gaily. Equally important is the fact that tests for drugs of abuse detected in
urine can provide only a very general and unreliable estimation of the time of
drug use, and a positive test result gives no indication of whether or not the
user's behavior was affected at the time of specimen collection.
Importance of the Medical History
Because these tests do not distinguish between drugs used legally and
those used illegally, it is important to obtain a record of relevant medical
information before test results are interpreted. The need to obtain this infor-
mation may pose a challenge to medical confidentiality, and this issue must
be resolved by the employer, the employee, and the employee's physician.
This is one of several reasons that it is important to use testing for drugs of
abuse only as part of a more comprehensive program.
Test Reliability
Again, a confirmed positive test result obtained by a reputable, quality-
conscious laboratory can be considered highly reliable as an indicator of ac-
tual drug use.
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RESULT REPORTING, SPECIMEN STORAGE,
AND
EXPERT TESTIMONY
Reporting
Most laboratories issue their results either by teleprinter or on computer-
ized report forms delivered by company couriers. Maintaining confidential-
ity is important for both ethical and legal reasons, and these reports should
be treated with the same care accorded medical reports.
In most cases, negative results are reported as "None Detected," and the
substances for which the laboratory was asked to test are listed. Positive
results are usually reported with the word "Detected" next to the substance
or substances identified in the sample.
Specimen Storage
Specimens should be stored by the laboratory for one to two weeks to
allow for retesting to settle any questions that may arise. In some cases, spec-
imens are sent to another laboratory for additional confirmatory testing. If
necessary, positive specimens can be stored for as long as two years to allow
for confirmation of test results in case of later disputes.
Expert Testimony
A conscientious laboratory will be willing to back up test results with ex-
pert testimony by qualified staff toxicologists and pathologists. Testimony
may be required on a variety of relevant issues, including the chain-of-
custody, test accuracy and reliability, interpretation of test results, quality
assurance prograrps, and laboratory methods, materials, and procedures.
CONCLUSION
As performed by a reputable laboratory, testing for drugs of abuse is both
highly accurate and reliable. However, this reliability is dependent on the
proper performance of a wide variety of functions. The laboratory must mon-
itor the entire testing system, from specimen pick-up to reporting of results.
Careful use of sophisticated equipment is in itself insufficient to provide reli-
able and legally viable results.
In choosing a laboratory, each client company must first assess its own
needs and then evaluate how those needs match the capabilities of the labo-
ratories under consideration. Important factors in choosing a laboratory in-
dude accuracy, service, turnaround time, and range of testing. Companies
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must also learn proper techniques for specimen collection and preparation,
since these critical functions are usually beyond the control of the laboratory.
In summary, drug screening tests offer an efficient means of excluding
negative specimens from further consideration. Specimens that produce
positive results on this initial screen must then be retested by an appropriate,
chemically different confirmatory method to eliminate any false positives. If
this procedure is followed by an established, quality-conscious laboratory,
the accuracy of a confirmed positive result should approach 100%. However,
it is important to be aware of the limitations of drugs-of-abuse testing when
interpreting test results. Because of these limitations, such testing is best
implemented as just one important element of a more comprehensive re-
sponse to employee drug abuse.
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